Total Chemoenzymatic Synthesis of (-)-3′-Methylaristeromycin

Abstract

Enantiopure ethyl (1S,4R)-4-hydroxy-2-methylcyclopent-2-ene-1-carboxylate, readily obtained by enzymatic kinetic resolution of the corresponding racemic derivative, provided a convenient starting building block for an 11-step chiral preparation of (-)-3′-methylaristeromycin with 23% overall yield.

aristeromycin - nucleobases - carbocyclic nucleosides - stereoselective synthesis - enzymatic regioselectivity

References and Notes

1a Kishi T. Muroi M. Kusaka T. Nishikawa M. Kamiya K. Mizuno K. J. Chem. Soc., Chem. Commun.  1967,  852 

1b Kusaka T. Yamamoto H. Shibata M. Muroi M. Kishi T. Mizuko K. J. Antibiot.  1968,  21:  255 

1c Kishi T. Muroi M. Kusaka T. Nishikawa M. Kamiya K. Mizuno K. Chem. Pharm. Bull.  1972,  20:  940 

2a Ueland PM. Pharmacol. Rev.  1982,  34:  223 

2b De Clercq E. Biochem. Pharmacol.  1987,  36:  2567 

2c Cools M. De Clercq E. Biochem. Pharmacol.  1989,  38:  1061 

2d De Clercq E. Nucleosides Nucleotides  1998,  17:  625 

2e De Clerq E. Nucleosides, Nucleotides Nucleic Acids  2005,  24:  1395 

3a Bennet LL. Brockman RW. Rose LM. Allan PW. Shaddix SC. Shealy YF. Clayton JD. Mol. Pharmacol.  1985,  27:  666 

3b Wolfe MS. Borchardt RT. J. Med. Chem.  1991,  34:  1521 

4 2′-Methylaristeromycin: Gosselin G. Griffe L. Meillon J.-C. Storer R. Tetrahedron  2006,  62:  906 

4′-Methylaristeromycin:

5a Wachtmeister J. Mühlman A. Classon B. Samuelsson B. Tetrahedron  1999,  55:  10761 

5b Gumina G. Chong Y. Choi Y. Chu CK. Org. Lett.  2000,  2:  1229 

5c Yin X.-q. Schneller SW. Tetrahedron Lett.  2006,  47:  4057 

6 5′-Methylaristeromycin: Ye W. Schneller SW. J. Org. Chem.  2006,  71:  8641 

7 Franchetti P. Cappellacci L. Pasqualini M. Petrelli R. Vita P. Jayaram HN. Horvath Z. Szekerers T. Grifantini M. J. Med. Chem.  2005,  48:  4983 

8 Aubin Y. Audran G. Monti H. Synlett  2006,  2215 

9 Audran G. Acherar S. Monti H. Eur. J. Org. Chem.  2003,  92 

10 Corey EJ. Venkateswarlu A. J. Am. Chem. Soc.  1972,  94:  6190 

For some rationalizations of OsO₄ selectivity, see:

11a Poli G. Tetrahedron Lett.  1989,  30:  7385 

11b Katagiri N. Ito Y. Kitano K. Toyota A. Konoko C. Chem. Pharm. Bull.  1994,  42:  2653 

11c Ward SE. Holmes AB. McCague R. Chem. Commun.  1997,  2085 

Some recent selected examples and references cited therein:

12a Trost BM. Madsen R. Guile SD. Brown B. J. Am. Chem. Soc.  2000,  122:  5947 

12b Brown B. Hegedus LS. J. Org. Chem.  2000,  65:  1865 

12c Donohoe TJ. Blades K. Moore PR. Waring MJ. Winter JJG. Helliwell M. Newcombe NJ. Stemp G. J. Org. Chem.  2002,  67:  7946 

12d Li F. Brogan JB. Gage JL. Zhang D. Miller MJ. J. Org. Chem.  2004,  69:  4538 

12e Ainai T. Wang Y.-G. Tokoro Y. Kobayashi Y. J. Org. Chem.  2004,  69:  655 

12f Jiang MX.-W. Jin B. Gage JL. Priour A. Savela G. Miller MJ. J. Org. Chem.  2006,  71:  4164 

13a Mitsunobu O. Synthesis  1981,  1 

13b Jenny TF. Horlacher J. Previsani N. Benner SA. Helv. Chim. Acta  1992,  75:  1944 

13c Review: Hughes DL. Org. Prep. Proced. Int.  1996,  28:  127 

14 Griffith WP. Ley SV. Aldrichimica Acta  1990,  23:  13 

15a Kazimierczuk Z. Revankar GR. Robins RK. Nucleic Acids Res.  1984,  12:  1179 

15b Kazimierczuk Z. Cottam HB. Revankar GR. Robins RK. J. Am. Chem. Soc.  1984,  106:  6379 

16

9-[(1′ R ,2′ S ,3′ R ,4′ R )-4′-Acetoxymethyl-2′,3′- O -isopropyl-idene-3′-methylcyclopent-1′-yl]adenine [(-)-11]: To a stirred solution of adenine (476 mg, 3.52 mmol, 2.5 equiv) in DMF (30 mL) at 0 °C under an argon atmosphere was added NaH (113 mg, 2.82 mmol, 2.0 equiv, 60% dispersion in mineral oil). The reaction mixture was heated to 60 °C and stirred at this temperature for 2 h. After cooling the solution to 0 °C, triflate (-)-10 (530 mg, 1.41 mmol) in DMF (3 mL) was added dropwise. After stirring for 2 h at 60 °C, the reaction mixture was concentrated in vacuo, and the residue was purified by column chromatography (CH₂Cl₂-MeOH) to give compound (-)-11 (380 mg, 75%) as a foam.

17

Characterization of selected new compounds:
Compound (+)-5: oil; [α]²⁵ _D +31.7 (c = 1.0, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ = 4.12-4.23 (m, 3 H), 3.94 (d, J = 1.8 Hz, 1 H), 2.95 (dd, J = 7.1, 11.3 Hz, 1 H), 2.32 (dt, J = 7.1, 13.6 Hz, 1 H), 2.06 (ddd, J = 7.1, 11.3, 13.6 Hz, 1 H), 1.49 (s, 3 H), 1.40 (s, 3 H), 1.35 (s, 3 H), 1.27 (t, J = 7.2 Hz, 3 H), 0.88 (s, 9 H), 0.08 (s, 3 H), 0.07 (s, 3 H). ¹³C NMR (75 MHz, CDCl₃): δ = 172.2 (C), 112.0 (C), 93.5 (CH), 88.5 (C), 74.8 (CH), 60.5 (CH₂), 53.3 (CH), 36.8 (CH₂), 28.3 (Me), 26.8 (Me), 25.7 (3 × Me), 21.7 (Me), 17.9 (C), 14.3 (Me), 4.9 (Me), 5.0 (Me). Anal. Calcd for C₁₈H₃₄O₅Si: C, 60.30; H, 9.56. Found: C, 60.19; H 9.59.
Compound (-)-10: white needles; mp 59-60 °C; [α]²⁵ _D -32.1 (c = 1.0, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ = 5.13 (ddd, J = 5.6, 7.0, 8.8 Hz, 1 H), 4.32 (d, J = 5.6 Hz, 1 H), 4.06, 4.00 (ABX, J = 4.8, 5.0, 11.6 Hz, 2 H), 2.50 (dt, J = 8.8, 12.5 Hz, 1 H), 2.38-2.44 (m, 1 H), 2.05 (s, 3 H), 1.98-2.05 (m partially overlapped, 1 H), 1.46 (s, 3 H), 1.42 (s, 3 H), 1.41 (s, 3 H). ¹³C NMR (75 MHz, CDCl₃): δ = 170.3 (C), 118.5 (q, J = 317 Hz, CF₃), 113.1 (C), 89.2 (C), 85.2 (CH), 84.4 (CH), 63.7 (CH₂), 44.2 (CH), 32.9 (CH₂), 27.6 (Me), 27.5 (Me), 21.6 (Me), 20.7 (Me). Anal. Calcd for C₁₃H₁₉F₃O₇S: C, 41.49; H, 5.09. Found: C, 41.73; H 5.13.
Compound (-)-11: [α]²⁵ _D -15.7 (c = 1.0, MeOH). ¹H NMR (300 MHz, DMSO-d ₆): δ = 8.26 (s, 1 H), 8.15 (s, 1 H), 7.26 (br s, 2 H), 4.91 (dt, J = 3.7, 9.5 Hz, 1 H), 4.51 (d, J = 3.7 Hz, 1 H), 4.12 (d, J = 6.8 Hz, 2 H), 2.40-2.46 (m, 1 H), 2.30-2.37 (m, 2 H), 2.01 (s, 3 H), 1.53 (s, 3 H), 1.46 (s, 3 H), 1.26 (s, 3 H). ¹³C NMR (75 MHz, DMSO-d ₆): δ = 170.4 (C), 156.1 (C), 152.4 (CH), 149.3 (C), 140.0 (CH), 119.3 (C), 112.8 (C), 90.4 (CH), 87.6 (C), 62.8 (CH₂), 58.4 (CH), 46.6 (CH), 34.0 (CH₂), 28.6 (Me), 27.2 (Me), 20.7 (Me), 20.5 (Me). Anal. Calcd for C₁₇H₂₃N₅O₄: C, 56.50; H, 6.41; N, 19.38. Found: C, 56.19; H, 6.37; N, 19.59.
Compound (-)-1: white solid; mp 146-147 °C; [α]²⁵ _D -10.5 (c = 1.0, MeOH). ¹H NMR (500 MHz, CD₃OD): δ = 8.22 (s, 1 H), 8.18 (s, 1 H), 4.87 (q, partially overlapped with HDO, J = 9.6 Hz, 1 H), 4.34 (d, J = 9.6 Hz, 1 H), 3.75 (d, J = 4.8 Hz, 2 H), 2.62 (dt, J = 9.6, 13.8 Hz, 1 H), 2.17 (dq, J = 4.8, 9.6 Hz, 1 H), 2.05 (ddd, J = 4.8, 9.6, 13.8 Hz, 1 H), 1.36 (s, 3 H). ¹³C NMR (125 MHz, CD₃OD): δ = 157.1 (C), 152.9 (CH), 150.7 (C), 142.3 (CH), 120.6 (C), 81.1 (CH), 78.8 (C), 63.9 (CH₂), 61.6 (CH), 48.7 (CH), 30.3 (CH₂), 21.6 (Me). Anal. Calcd for C₁₂H₁₇O₃N₅: C, 51.60; H, 6.13; N, 25.07. Found: C, 51.99; H, 6.09; N, 24.79.

18a Crimmins MT. Tetrahedron  1998,  54:  9229 

18b Ferrero M. Gotor V. Chem. Rev.  2000,  100:  4319 

18c Zhu XF. Nucleosides, Nucleotides Nucleic Acids  2000,  19:  651 

18d Rodriguez JB. Comin MJ. Mini-Rev. Med. Chem.  2003,  3:  95 

19a Lott WB. Chagovetz AM. Grissom CB. J. Am. Chem. Soc.  1995,  117:  12194 

19b Shuto S. Shirato M. Sumita Y. Ueno Y. Matsuda A. J. Org. Chem.  1998,  63:  1986 

19c Fukuoka M. Shuto S. Minakawa N. Ueno Y. Matsuda A. Tetrahedron Lett.  1999,  40:  5361